Michael J. Perry


Michael Perry Photo

Washington, D.C.

P: +1.202.639.1318 F: +1.202.585.1024
  • Represented RealPage in its acquisition of Lease Rent Options and related assets from the Rainmaker Group.
  • Represented Rockwater Energy Solutions in its merger with Select Energy Solutions.
  • Sony v. Fujifilm (S.D.N.Y.). Representing Fujifilm in antitrust litigation and related actions relating to magnetic tape cartridges.
  • Haier America Trading v. Samsung Electronics (N.D.N.Y.). Representing Columbia University in antitrust and other claims involving digital television technology.
  • California v. Valero (N.D. Cal.) Represented Valero Energy in the California Attorney General’s challenge to the proposed acquisition of Plains All American Pipeline’s Bay Area terminals.
  • Advising leading pharmaceutical company on Hatch-Waxman patent settlements.
  • Representing healthcare trade associations in connection with federal antitrust investigations.
  • Represented leading pharmaceutical company in worldwide research, development, and commercialization collaboration.

While at the FTC, Mr. Perry's experience included:

  • Supervising merger and non-merger investigations in the healthcare, pharmaceutical, retail, grocery, energy, and technology industries.
  • FTC v. Cephalon (E.D. Pa.). Responsible for major components of the FTC's enforcement action alleging unlawful reverse-payment patent settlements, which resulted in the largest monetary settlement in agency history.
  • FTC v. Sysco (D.D.C.). Actively involved in the FTC's challenge to the proposed merger of Sysco and U.S. Foods.
  • FTC v. St. Luke's Health System (D. Idaho). Represented the FTC at trial and post-trial proceedings in challenge to a consummated healthcare merger.
  • FTC v. Actavis (N.D. Ga.). Following grant of certiorari, briefed and argued motion to unseal an exhibit attached to the FTC's complaint, which became part of the public Supreme Court record.
  • Actelion Pharmaceuticals v. Apotex (D.N.J.). Lead author of FTC amicus brief addressing whether a pharmaceutical company's refusal to sell product samples to generic competitors may violate the antitrust laws.